chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Anticoagulant therapy, Atrial fibrillation, Blood bicarbonate normal
Clinical narrative: Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Blood gases abnormal, Blood pH normal, CHA2DS2-VASc-score, COVID-19, Cardiac failure
Clinical narrative: Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Confusional state, Deep vein thrombosis, Echocardiogram abnormal, Ejection fraction decreased, Electrocardiogram abnormal
Clinical narrative: Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Hypercoagulation, Leukocytosis, Lung consolidation, Lung opacity, Myocardial ischaemia
Clinical narrative: Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Myocardial strain imaging abnormal, PCO2 decreased, PO2 normal, Pneumonia, Pulmonary artery dilatation
Clinical narrative: Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Pulmonary embolism, Respiratory failure, SARS-CoV-2 test positive, Supraventricular extrasystoles, Troponin increased
Clinical narrative: Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Ultrasound Doppler abnormal, White blood cell count increased
Clinical narrative: Acute Hypoxemic, Hypercapnic Respiratory Failure, resolved - Secondary to bilateral PEs and COVID-19 infection below, on room air at baseline - 1/28 VBG: pH 7.41, pCO2 37.7, pO2 50, HCO3 24.0 - Weaned to room air with treatment as below     Intermediate-Low Risk Pulmonary Embolism - Bilateral LE DVTs below with elevated troponin's and evidence of right heart strain on imaging,  PESI: 117, Class IV, High Risk - 1/28 CT PA large PE within bilateral main pulmonary arteries of all lung lobes, evidence of right heart strain, pulmonary artery enlarged, moderate leukocytosis - 1/29 TTE normal RV dimensions and function, possible pulmonary hypertension - Peripheral Vascular followed, transitioned to Xarelto, follow up with PV in 1 month as outpatient   Bilateral Lower Extremity DVTs - In the setting of hypercoagulable state secondary to COVID-19 infection - 1/28 LE dopplers: DVT in left gastrocnemius, DVTs reaching as superiorly as popliteal vein on the right - Continue anticoagulation per above   COVID-19 Infection Community Acquired Pneumonia  - Patient denies any symptoms or sick contacts, received 3 vaccines (uncertain which ones) - 1/28 COVID-19 PCR positive, CT PA focal consolidation bilateral lower lobes, regional area groundglass opacity in right lower lobe, moderate leukocytosis - S/p ceftriaxone 1/29, azithromycin (1/29-1/30) and decadron 6 mg (1/28-1/30) - Will complete 4 days of po Augmentin for treatment of CAP   Paroxysmal Atrial Fibrillation with RVR - Likely secondary to heart strain due to PE, per patient no history of atrial fibrillation - 1/28 EKG may have been sinus rhythm with frequent PACs causing confusion for atrial fibrillation - CHADS-VASc = 4 - Will be discharged on Xarelto as above with outpatient follow-up with peripheral vascular   Elevated Troponin - Most likely Type II Demand Ischemia in setting of PE above - Trop 51 -> 45, negative delta   Leukocytosis, resolving - Reactive in setting of above - WBC 20.77 on admission decreased to 17K on discharge - Repeat CBC in 1 week   HF recovered EF - 4/22/21 TTE LVEF 20-25% - 1/29/23 TTE LVEF 61% - Home medication: losartan 25 mg daily - Consider escalating therapy with addition of beta blocker and SGLT2 inhibitor
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Blood bicarbonate increased, Blood gases abnormal, COVID-19, Chest X-ray normal
Clinical narrative: Patient is a 90 y.o. female patient of CNP with history of COPD, dementia, hyperlipidemia, hypothyroidism, history of CVA, history of seizure, chronic hypoxic respiratory failure likely oxygen only, who presented to the emergency room with shortness of breath and cough with minimal phlegm production, found to have COVID.    Acute hypoxemic hypercarbic respiratory failure Pneumonia secondary to COVID Concern of secondary bacterial pneumonia COPD with acute exacerbation Chronically on 2 L of oxygen at night only ABG on admission, PCO2 64 0.7, bicarb 35, bicarb 10 days ago was 27.  Acute CO2 retention.  Initially on BiPAP currently on 2 L of oxygen through nasal cannula.  Wean oxygen as tolerated. Procalcitonin normal.  Chest x-ray without any infiltrates. Unlikely superimposed pneumonia.  Stop antibiotics per Remdesivir, steroid. Symbicort and albuterol scheduled and as needed. Advair on discharge Dexa for 4 more days on discharge   Hypothyroidism, levothyroxine Seizure, Keppra History of CVA, aspirin and statin Hypertension, Imdur Still remains uncontrolled, add low-dose of lisinopril. Repeat labs tomorrow.   Covid-19 Virus Infection Date of onset of symptoms: 1/18/22 Symptoms present on admission: shortness of breath  Date of covid positive test: 1/19/22 Vaccination status: vaccinated Imaging: xary  Oxygen requirements on admission: 15 L nonrebreather then BiPAP Current oxygen requirements: 2 L NC Medical therapy: remdesivir and steroids Consultants following: Infectious disease Anticipated special isolation end date: 1/29/22    Severe protein calorie malnutrition Body mass index 14.8 Nutrition consult  Physical deconditioning Chronic fatigue syndrome PT OT Social service consult.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Condition aggravated, Dyspnoea, Hypercapnia
Clinical narrative: Patient is a 90 y.o. female patient of CNP with history of COPD, dementia, hyperlipidemia, hypothyroidism, history of CVA, history of seizure, chronic hypoxic respiratory failure likely oxygen only, who presented to the emergency room with shortness of breath and cough with minimal phlegm production, found to have COVID.    Acute hypoxemic hypercarbic respiratory failure Pneumonia secondary to COVID Concern of secondary bacterial pneumonia COPD with acute exacerbation Chronically on 2 L of oxygen at night only ABG on admission, PCO2 64 0.7, bicarb 35, bicarb 10 days ago was 27.  Acute CO2 retention.  Initially on BiPAP currently on 2 L of oxygen through nasal cannula.  Wean oxygen as tolerated. Procalcitonin normal.  Chest x-ray without any infiltrates. Unlikely superimposed pneumonia.  Stop antibiotics per Remdesivir, steroid. Symbicort and albuterol scheduled and as needed. Advair on discharge Dexa for 4 more days on discharge   Hypothyroidism, levothyroxine Seizure, Keppra History of CVA, aspirin and statin Hypertension, Imdur Still remains uncontrolled, add low-dose of lisinopril. Repeat labs tomorrow.   Covid-19 Virus Infection Date of onset of symptoms: 1/18/22 Symptoms present on admission: shortness of breath  Date of covid positive test: 1/19/22 Vaccination status: vaccinated Imaging: xary  Oxygen requirements on admission: 15 L nonrebreather then BiPAP Current oxygen requirements: 2 L NC Medical therapy: remdesivir and steroids Consultants following: Infectious disease Anticipated special isolation end date: 1/29/22    Severe protein calorie malnutrition Body mass index 14.8 Nutrition consult  Physical deconditioning Chronic fatigue syndrome PT OT Social service consult.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Malnutrition, PCO2 increased, Physical deconditioning, Pneumonia
Clinical narrative: Patient is a 90 y.o. female patient of CNP with history of COPD, dementia, hyperlipidemia, hypothyroidism, history of CVA, history of seizure, chronic hypoxic respiratory failure likely oxygen only, who presented to the emergency room with shortness of breath and cough with minimal phlegm production, found to have COVID.    Acute hypoxemic hypercarbic respiratory failure Pneumonia secondary to COVID Concern of secondary bacterial pneumonia COPD with acute exacerbation Chronically on 2 L of oxygen at night only ABG on admission, PCO2 64 0.7, bicarb 35, bicarb 10 days ago was 27.  Acute CO2 retention.  Initially on BiPAP currently on 2 L of oxygen through nasal cannula.  Wean oxygen as tolerated. Procalcitonin normal.  Chest x-ray without any infiltrates. Unlikely superimposed pneumonia.  Stop antibiotics per Remdesivir, steroid. Symbicort and albuterol scheduled and as needed. Advair on discharge Dexa for 4 more days on discharge   Hypothyroidism, levothyroxine Seizure, Keppra History of CVA, aspirin and statin Hypertension, Imdur Still remains uncontrolled, add low-dose of lisinopril. Repeat labs tomorrow.   Covid-19 Virus Infection Date of onset of symptoms: 1/18/22 Symptoms present on admission: shortness of breath  Date of covid positive test: 1/19/22 Vaccination status: vaccinated Imaging: xary  Oxygen requirements on admission: 15 L nonrebreather then BiPAP Current oxygen requirements: 2 L NC Medical therapy: remdesivir and steroids Consultants following: Infectious disease Anticipated special isolation end date: 1/29/22    Severe protein calorie malnutrition Body mass index 14.8 Nutrition consult  Physical deconditioning Chronic fatigue syndrome PT OT Social service consult.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Positive airway pressure therapy, Procalcitonin normal, Productive cough, Respiratory failure, SARS-CoV-2 test positive
Clinical narrative: Patient is a 90 y.o. female patient of CNP with history of COPD, dementia, hyperlipidemia, hypothyroidism, history of CVA, history of seizure, chronic hypoxic respiratory failure likely oxygen only, who presented to the emergency room with shortness of breath and cough with minimal phlegm production, found to have COVID.    Acute hypoxemic hypercarbic respiratory failure Pneumonia secondary to COVID Concern of secondary bacterial pneumonia COPD with acute exacerbation Chronically on 2 L of oxygen at night only ABG on admission, PCO2 64 0.7, bicarb 35, bicarb 10 days ago was 27.  Acute CO2 retention.  Initially on BiPAP currently on 2 L of oxygen through nasal cannula.  Wean oxygen as tolerated. Procalcitonin normal.  Chest x-ray without any infiltrates. Unlikely superimposed pneumonia.  Stop antibiotics per Remdesivir, steroid. Symbicort and albuterol scheduled and as needed. Advair on discharge Dexa for 4 more days on discharge   Hypothyroidism, levothyroxine Seizure, Keppra History of CVA, aspirin and statin Hypertension, Imdur Still remains uncontrolled, add low-dose of lisinopril. Repeat labs tomorrow.   Covid-19 Virus Infection Date of onset of symptoms: 1/18/22 Symptoms present on admission: shortness of breath  Date of covid positive test: 1/19/22 Vaccination status: vaccinated Imaging: xary  Oxygen requirements on admission: 15 L nonrebreather then BiPAP Current oxygen requirements: 2 L NC Medical therapy: remdesivir and steroids Consultants following: Infectious disease Anticipated special isolation end date: 1/29/22    Severe protein calorie malnutrition Body mass index 14.8 Nutrition consult  Physical deconditioning Chronic fatigue syndrome PT OT Social service consult.
Age: 56.0
Sex: F
Vaccine: UNK
Symptoms: Cough, Dyspnoea, Feeling abnormal, Insomnia, Lip swelling
Clinical narrative: I started feeling a little weird a few hours after taking the Pfizer booster.  By the evening I had a slight runny nose and itchy in my upper arms.  By Tuesday morning, runny nose, itchy throat and stuffy nose.  I sort felt a little better on Wednesday morning, only to have an unstoppable runny nose, itchy throat, arms, legs, stomach and face and a dry cough.   I had a really rough weekend due to unable to breathe normally through my nose, dry cough, unable to sleep.  It feels like an Asthma attack.  Right now, I have patches all over my face, my lips are swollen and have black patches on them.  Still coughing, still itching all over and dealing a runny nose.
Age: 56.0
Sex: F
Vaccine: UNK
Symptoms: Nasal congestion, Pruritus, Rhinorrhoea, Skin discolouration, Throat irritation
Clinical narrative: I started feeling a little weird a few hours after taking the Pfizer booster.  By the evening I had a slight runny nose and itchy in my upper arms.  By Tuesday morning, runny nose, itchy throat and stuffy nose.  I sort felt a little better on Wednesday morning, only to have an unstoppable runny nose, itchy throat, arms, legs, stomach and face and a dry cough.   I had a really rough weekend due to unable to breathe normally through my nose, dry cough, unable to sleep.  It feels like an Asthma attack.  Right now, I have patches all over my face, my lips are swollen and have black patches on them.  Still coughing, still itching all over and dealing a runny nose.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Chest X-ray, Chronic obstructive pulmonary disease, Condition aggravated
Clinical narrative: Patient is a 78 y.o. male patient of DO with history of COPD, chronic hypoxemic respiratory failure, paroxysmal atrial fibrillation, HTN, cardiomyopathy, Essential tremors who presented on 1/18/2023 with a fall. Consulted by MD for medical management.      Covid-19 Virus Infection Date of onset of symptoms: 1/20 Symptoms present on admission: s/p fall, cough and fever Date of covid positive test: 1/20 Vaccination status: vaccinated Imaging: Chest Xray  Oxygen requirements on admission: 3L NC  Current oxygen requirements: 3L NC  Medical therapy: Remdesivir and Solu-Medrol Consultants following: ID Anticipated special isolation end date: 1/30      Acute on chronic hypoxemic respiratory failure Acute COPD exacerbation - end stage COPD Pulmonary Hypertension Wears 3L per NC at HS only Goal SpO2 >88% - 92% - Avoid hyper-oxygenation.  Give Duoneb treatments x2 now Check ABG Increase frequency of scheduled bronchodilators to q4h/2h PRN Change Symbicort to Pulmicort BID while in acute exacerbation Add IV steroids (uses chronic prednisone therapy) Add Singulair, Mucinex BID.  Was on  Azithromycin IV daily Continue Spiriva Cautious use of benzodiazepines in acute exacerbation.  NIPPV PRN Treatment of COVID as above Discontinue IV ceftriaxone azithromycin   Fall Thoracic/Lumbar Compression Fracture Left orbital hematoma/abrasion Management per trauma services and neurosurgery. PT/OT.   Urinary Retention UTI with E. coli History of chronic self catheterizations. Urology consulted. Antibiotic discontinued by infectious disease team Cardiomyopathy Chronic diastolic heart failure History of EF 10-15% with recovery Last TTE 7/2021: Normal LV size and systolic function. LVEF 60%; RV dilation with reduced RV function; pulmonary hypertension.  Monitor fluid balances closely.  Strict I/O   Paroxysmal atrial fibrillation Not on AC due to bleeding issues  Continue amiodarone and digoxin
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Escherichia infection, Eye abrasion, Fall, Orbital haematoma
Clinical narrative: Patient is a 78 y.o. male patient of DO with history of COPD, chronic hypoxemic respiratory failure, paroxysmal atrial fibrillation, HTN, cardiomyopathy, Essential tremors who presented on 1/18/2023 with a fall. Consulted by MD for medical management.      Covid-19 Virus Infection Date of onset of symptoms: 1/20 Symptoms present on admission: s/p fall, cough and fever Date of covid positive test: 1/20 Vaccination status: vaccinated Imaging: Chest Xray  Oxygen requirements on admission: 3L NC  Current oxygen requirements: 3L NC  Medical therapy: Remdesivir and Solu-Medrol Consultants following: ID Anticipated special isolation end date: 1/30      Acute on chronic hypoxemic respiratory failure Acute COPD exacerbation - end stage COPD Pulmonary Hypertension Wears 3L per NC at HS only Goal SpO2 >88% - 92% - Avoid hyper-oxygenation.  Give Duoneb treatments x2 now Check ABG Increase frequency of scheduled bronchodilators to q4h/2h PRN Change Symbicort to Pulmicort BID while in acute exacerbation Add IV steroids (uses chronic prednisone therapy) Add Singulair, Mucinex BID.  Was on  Azithromycin IV daily Continue Spiriva Cautious use of benzodiazepines in acute exacerbation.  NIPPV PRN Treatment of COVID as above Discontinue IV ceftriaxone azithromycin   Fall Thoracic/Lumbar Compression Fracture Left orbital hematoma/abrasion Management per trauma services and neurosurgery. PT/OT.   Urinary Retention UTI with E. coli History of chronic self catheterizations. Urology consulted. Antibiotic discontinued by infectious disease team Cardiomyopathy Chronic diastolic heart failure History of EF 10-15% with recovery Last TTE 7/2021: Normal LV size and systolic function. LVEF 60%; RV dilation with reduced RV function; pulmonary hypertension.  Monitor fluid balances closely.  Strict I/O   Paroxysmal atrial fibrillation Not on AC due to bleeding issues  Continue amiodarone and digoxin
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Respiratory failure, SARS-CoV-2 test positive, Spinal compression fracture, Urinary retention
Clinical narrative: Patient is a 78 y.o. male patient of DO with history of COPD, chronic hypoxemic respiratory failure, paroxysmal atrial fibrillation, HTN, cardiomyopathy, Essential tremors who presented on 1/18/2023 with a fall. Consulted by MD for medical management.      Covid-19 Virus Infection Date of onset of symptoms: 1/20 Symptoms present on admission: s/p fall, cough and fever Date of covid positive test: 1/20 Vaccination status: vaccinated Imaging: Chest Xray  Oxygen requirements on admission: 3L NC  Current oxygen requirements: 3L NC  Medical therapy: Remdesivir and Solu-Medrol Consultants following: ID Anticipated special isolation end date: 1/30      Acute on chronic hypoxemic respiratory failure Acute COPD exacerbation - end stage COPD Pulmonary Hypertension Wears 3L per NC at HS only Goal SpO2 >88% - 92% - Avoid hyper-oxygenation.  Give Duoneb treatments x2 now Check ABG Increase frequency of scheduled bronchodilators to q4h/2h PRN Change Symbicort to Pulmicort BID while in acute exacerbation Add IV steroids (uses chronic prednisone therapy) Add Singulair, Mucinex BID.  Was on  Azithromycin IV daily Continue Spiriva Cautious use of benzodiazepines in acute exacerbation.  NIPPV PRN Treatment of COVID as above Discontinue IV ceftriaxone azithromycin   Fall Thoracic/Lumbar Compression Fracture Left orbital hematoma/abrasion Management per trauma services and neurosurgery. PT/OT.   Urinary Retention UTI with E. coli History of chronic self catheterizations. Urology consulted. Antibiotic discontinued by infectious disease team Cardiomyopathy Chronic diastolic heart failure History of EF 10-15% with recovery Last TTE 7/2021: Normal LV size and systolic function. LVEF 60%; RV dilation with reduced RV function; pulmonary hypertension.  Monitor fluid balances closely.  Strict I/O   Paroxysmal atrial fibrillation Not on AC due to bleeding issues  Continue amiodarone and digoxin
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Urinary tract infection
Clinical narrative: Patient is a 78 y.o. male patient of DO with history of COPD, chronic hypoxemic respiratory failure, paroxysmal atrial fibrillation, HTN, cardiomyopathy, Essential tremors who presented on 1/18/2023 with a fall. Consulted by MD for medical management.      Covid-19 Virus Infection Date of onset of symptoms: 1/20 Symptoms present on admission: s/p fall, cough and fever Date of covid positive test: 1/20 Vaccination status: vaccinated Imaging: Chest Xray  Oxygen requirements on admission: 3L NC  Current oxygen requirements: 3L NC  Medical therapy: Remdesivir and Solu-Medrol Consultants following: ID Anticipated special isolation end date: 1/30      Acute on chronic hypoxemic respiratory failure Acute COPD exacerbation - end stage COPD Pulmonary Hypertension Wears 3L per NC at HS only Goal SpO2 >88% - 92% - Avoid hyper-oxygenation.  Give Duoneb treatments x2 now Check ABG Increase frequency of scheduled bronchodilators to q4h/2h PRN Change Symbicort to Pulmicort BID while in acute exacerbation Add IV steroids (uses chronic prednisone therapy) Add Singulair, Mucinex BID.  Was on  Azithromycin IV daily Continue Spiriva Cautious use of benzodiazepines in acute exacerbation.  NIPPV PRN Treatment of COVID as above Discontinue IV ceftriaxone azithromycin   Fall Thoracic/Lumbar Compression Fracture Left orbital hematoma/abrasion Management per trauma services and neurosurgery. PT/OT.   Urinary Retention UTI with E. coli History of chronic self catheterizations. Urology consulted. Antibiotic discontinued by infectious disease team Cardiomyopathy Chronic diastolic heart failure History of EF 10-15% with recovery Last TTE 7/2021: Normal LV size and systolic function. LVEF 60%; RV dilation with reduced RV function; pulmonary hypertension.  Monitor fluid balances closely.  Strict I/O   Paroxysmal atrial fibrillation Not on AC due to bleeding issues  Continue amiodarone and digoxin
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, C-reactive protein increased, COVID-19, Chest X-ray abnormal, Dyspnoea
Clinical narrative: Patient is a 75 y.o. female with history of  ESRD presented to the Hospital with shortness of breath.  Patient admitted with acute hypoxic respiratory failure secondary to fluid overload from missed hemodialysis as well as found to have COVID-19 infection, sepsis with possibility of bacterial pneumonia.   Acute hypoxic respiratory failure  Likely due fluid overload COVID 19 infection  Chest X ray showed: Mild vascular congestion is suggested.There appears to be increased density in the left lung base which may be due to a small left-sided pleural effusion.  There could be underlying atelectasis or infiltrate. -Overnight respiratory status decompensated, placed on BiPAP -Likely due to pulmonary edema from missed hemodialysis -S/p hemodialysis with improvement -Weaned down to 2 L O2 -Given high O2 requirement, elevated procalcitonin also initiated on broad-spectrum antibiotics. -Continue to wean O2 as tolerated, aggressive pulmonary hygiene. Qualified for home O2 at discharge     Covid-19 Virus Infection Date of onset of symptoms: Unknown Symptoms present on admission: Yes Date of covid positive test: 1/19/2023 Vaccination status: vaccinated Imaging: Chest x-ray with increased density left lung base Oxygen requirements on admission: Nasal cannula 2 L Current oxygen requirements: 6 L NC Medical therapy: remdesivir and steroids Finish 10 day course of dexamethasone. Completed 4 days of remdesivir Consultants following: Infectious disease Anticipated special isolation end date: 1/29/2023  SIRS- sepsis ruled out Possible CAP -Leukocytosis noted at 15 suspect reactive -Procalcitonin 0.8, CRP 27 -Given mildly elevated procalcitonin,  and SIRS  started on ceftriaxone and azithromycin -Continue to monitor -patient oliguric - Improved over all - Transitioned to oral antibiotic for total 7 days   ESRD  Hyponatremia likely hypervolemic  Hyperkalemia on MWF Follow nephrology recommendations regarding hemodialysis Improved overall   GERD On Protonix    Typ II DM insulin-dependent Hold glipizide Monitor insulin sliding scale Stable   Essential HTN  Not clear if she is on Norvasc or Nifedipine Hold losartan and Norvasc Continue with labetalol and nifedipine Stable BP   Elevated troponin  Likely due to ESRD
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Hypervolaemia, Leukocytosis, Malaise, Pleural effusion, Positive airway pressure therapy
Clinical narrative: Patient is a 75 y.o. female with history of  ESRD presented to the Hospital with shortness of breath.  Patient admitted with acute hypoxic respiratory failure secondary to fluid overload from missed hemodialysis as well as found to have COVID-19 infection, sepsis with possibility of bacterial pneumonia.   Acute hypoxic respiratory failure  Likely due fluid overload COVID 19 infection  Chest X ray showed: Mild vascular congestion is suggested.There appears to be increased density in the left lung base which may be due to a small left-sided pleural effusion.  There could be underlying atelectasis or infiltrate. -Overnight respiratory status decompensated, placed on BiPAP -Likely due to pulmonary edema from missed hemodialysis -S/p hemodialysis with improvement -Weaned down to 2 L O2 -Given high O2 requirement, elevated procalcitonin also initiated on broad-spectrum antibiotics. -Continue to wean O2 as tolerated, aggressive pulmonary hygiene. Qualified for home O2 at discharge     Covid-19 Virus Infection Date of onset of symptoms: Unknown Symptoms present on admission: Yes Date of covid positive test: 1/19/2023 Vaccination status: vaccinated Imaging: Chest x-ray with increased density left lung base Oxygen requirements on admission: Nasal cannula 2 L Current oxygen requirements: 6 L NC Medical therapy: remdesivir and steroids Finish 10 day course of dexamethasone. Completed 4 days of remdesivir Consultants following: Infectious disease Anticipated special isolation end date: 1/29/2023  SIRS- sepsis ruled out Possible CAP -Leukocytosis noted at 15 suspect reactive -Procalcitonin 0.8, CRP 27 -Given mildly elevated procalcitonin,  and SIRS  started on ceftriaxone and azithromycin -Continue to monitor -patient oliguric - Improved over all - Transitioned to oral antibiotic for total 7 days   ESRD  Hyponatremia likely hypervolemic  Hyperkalemia on MWF Follow nephrology recommendations regarding hemodialysis Improved overall   GERD On Protonix    Typ II DM insulin-dependent Hold glipizide Monitor insulin sliding scale Stable   Essential HTN  Not clear if she is on Norvasc or Nifedipine Hold losartan and Norvasc Continue with labetalol and nifedipine Stable BP   Elevated troponin  Likely due to ESRD
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Procalcitonin increased, Pulmonary oedema, Respiratory disorder, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: Patient is a 75 y.o. female with history of  ESRD presented to the Hospital with shortness of breath.  Patient admitted with acute hypoxic respiratory failure secondary to fluid overload from missed hemodialysis as well as found to have COVID-19 infection, sepsis with possibility of bacterial pneumonia.   Acute hypoxic respiratory failure  Likely due fluid overload COVID 19 infection  Chest X ray showed: Mild vascular congestion is suggested.There appears to be increased density in the left lung base which may be due to a small left-sided pleural effusion.  There could be underlying atelectasis or infiltrate. -Overnight respiratory status decompensated, placed on BiPAP -Likely due to pulmonary edema from missed hemodialysis -S/p hemodialysis with improvement -Weaned down to 2 L O2 -Given high O2 requirement, elevated procalcitonin also initiated on broad-spectrum antibiotics. -Continue to wean O2 as tolerated, aggressive pulmonary hygiene. Qualified for home O2 at discharge     Covid-19 Virus Infection Date of onset of symptoms: Unknown Symptoms present on admission: Yes Date of covid positive test: 1/19/2023 Vaccination status: vaccinated Imaging: Chest x-ray with increased density left lung base Oxygen requirements on admission: Nasal cannula 2 L Current oxygen requirements: 6 L NC Medical therapy: remdesivir and steroids Finish 10 day course of dexamethasone. Completed 4 days of remdesivir Consultants following: Infectious disease Anticipated special isolation end date: 1/29/2023  SIRS- sepsis ruled out Possible CAP -Leukocytosis noted at 15 suspect reactive -Procalcitonin 0.8, CRP 27 -Given mildly elevated procalcitonin,  and SIRS  started on ceftriaxone and azithromycin -Continue to monitor -patient oliguric - Improved over all - Transitioned to oral antibiotic for total 7 days   ESRD  Hyponatremia likely hypervolemic  Hyperkalemia on MWF Follow nephrology recommendations regarding hemodialysis Improved overall   GERD On Protonix    Typ II DM insulin-dependent Hold glipizide Monitor insulin sliding scale Stable   Essential HTN  Not clear if she is on Norvasc or Nifedipine Hold losartan and Norvasc Continue with labetalol and nifedipine Stable BP   Elevated troponin  Likely due to ESRD
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Sepsis, Systemic inflammatory response syndrome, Troponin increased, White blood cell count increased
Clinical narrative: Patient is a 75 y.o. female with history of  ESRD presented to the Hospital with shortness of breath.  Patient admitted with acute hypoxic respiratory failure secondary to fluid overload from missed hemodialysis as well as found to have COVID-19 infection, sepsis with possibility of bacterial pneumonia.   Acute hypoxic respiratory failure  Likely due fluid overload COVID 19 infection  Chest X ray showed: Mild vascular congestion is suggested.There appears to be increased density in the left lung base which may be due to a small left-sided pleural effusion.  There could be underlying atelectasis or infiltrate. -Overnight respiratory status decompensated, placed on BiPAP -Likely due to pulmonary edema from missed hemodialysis -S/p hemodialysis with improvement -Weaned down to 2 L O2 -Given high O2 requirement, elevated procalcitonin also initiated on broad-spectrum antibiotics. -Continue to wean O2 as tolerated, aggressive pulmonary hygiene. Qualified for home O2 at discharge     Covid-19 Virus Infection Date of onset of symptoms: Unknown Symptoms present on admission: Yes Date of covid positive test: 1/19/2023 Vaccination status: vaccinated Imaging: Chest x-ray with increased density left lung base Oxygen requirements on admission: Nasal cannula 2 L Current oxygen requirements: 6 L NC Medical therapy: remdesivir and steroids Finish 10 day course of dexamethasone. Completed 4 days of remdesivir Consultants following: Infectious disease Anticipated special isolation end date: 1/29/2023  SIRS- sepsis ruled out Possible CAP -Leukocytosis noted at 15 suspect reactive -Procalcitonin 0.8, CRP 27 -Given mildly elevated procalcitonin,  and SIRS  started on ceftriaxone and azithromycin -Continue to monitor -patient oliguric - Improved over all - Transitioned to oral antibiotic for total 7 days   ESRD  Hyponatremia likely hypervolemic  Hyperkalemia on MWF Follow nephrology recommendations regarding hemodialysis Improved overall   GERD On Protonix    Typ II DM insulin-dependent Hold glipizide Monitor insulin sliding scale Stable   Essential HTN  Not clear if she is on Norvasc or Nifedipine Hold losartan and Norvasc Continue with labetalol and nifedipine Stable BP   Elevated troponin  Likely due to ESRD
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Lung infiltration, Malaise, Metabolic function test, Metastasis, Nausea
Clinical narrative: Patient is 77 years old with past medical history of COPD, atrial flutter, hypertension, hyperlipidemia, diabetes mellitus, asthma, chronic respiratory failure presented to the hospital with a chief complaint of shortness of breath associated with cough, reduced appetite, fatigue and malaise.  Admits to mild nausea intermittently.  Patient was recently in the ER and attempt to treated outpatient has failed.  He noticed worsening of his symptoms.  And he returned back.  Otherwise patient has no fever, chills, abdominal pain, diarrhea, constipation, difficulty urination, dysuria   In the ED, patient was noted to have elevated troponin.  Cardiology was consulted and an echocardiogram was done.  From cardiology the elevated troponin is likely due to the COVID infection.  Patient had a CTA done which was negative for pulmonary embolism.  CTA was significant for an infiltrate.  Patient was initiated on broad-spectrum hospital-acquired antibiotic.  Venous ABG was done with a PCO2 of 53.  Patient was noted to have hyponatremia and hypokalemia on labs.  HPI per admitting hospitalist.      Clinical Summary   Clinical course Include/ Problem list Acute on chronic hypoxic and hypercapnic respiratory failure Covid-19 -Continue supplemental oxygen -Paxlovid stopped on admission -Continue IV remdesivir (final dose scheduled for 1/18) -Continue IV dexamethasone -Continue albuterol inhaler scheduled and as needed -Continue Spiriva -Continue twice daily Mucinex, twice daily vitamin C, daily vitamin D and zinc -Pulmonology consulted and following   Postobstructive pneumonia -Associated with hilar mass -Continue Zosyn and azithromycin -- >per pulmonology: plan for 2 weeks Augmentin unless cultures indicate otherwise  -Pulmonology consulted and following   Acute exacerbation of COPD, Emphysema -Secondary to above -Continue plan as above   Moderate acute hyponatremia POA -Improving  -Na 135 (on presentation 120) -Continue to monitor   Elevated troponin, likely type II NSTEMI -No chest pain -Cardiology consulted while patient was in the ER  -EKG on admission shows normal sinus rhythm with nonspecific T wave changes -No regional wall motion abnormalities on echocardiogram -Secondary to acute illness as above -Maintained on Eliquis -no abnormalities noted on telemetry  Leukocytosis -likely 2/2 steroids -WBC 13.32  -afebrile -continue to monitor    Transaminitis -improving -Secondary to acute illness vs Paxlovid? -AST 38, ALT 76 -Normal alk phos, bili -Hepatitis panel: Negative  -GGT WNL -Daily CMP   Hilar mass, concern for metastasis vs second lung primary -Larger than prior, measuring 4.8 x 3.0 x 3.2 -Associated with new reticular nodule infiltrates within the left upper lobe, inflammatory versus neoplastic -Follows with Dr., concern for progression of disease -Pending PET scan; May need biopsy -Consulted pulmonology: delay any procedure for minimum 2 weeks d/t current Covid -follow-up with oncology and radiation as OP   Squamous cell carcinoma of the tongue -Follows with Dr., underwent chemo, radiation, and immunotherapy.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Acute respiratory failure, Adult failure to thrive, Anxiety, Aortic aneurysm
Clinical narrative: Patient is a 73 y.o. male patient with history of hypertension, now presented after a fall at home.  Patient became acutely hypoxic on 1/26/2023 morning.  Transferred to ICU where he developed asystole and passed away at 12:09 PM     Acute hypoxic respiratory failure PEA cardiac arrest COVID-19 infection became acutely hypoxic on 1/26/2023.  Stat chest x-ray, troponin, proBNP, lactic acid ordered Discussed with patient's wife on the phone and she confirmed that patient is DNR CCA/DNI, also reviewed docs in chart Patient developed PEA cardiac arrest at 12:09 PM on 1/26/2023   Fall, initial encounter Weakness and fatigue Failure to thrive CT head with no intracranial injury Scalp wound stapled in ER   Metastatic liver cancer Large liver mass at the hepatic hilum Cholangiocarcinoma Followed with Dr.   Acute kidney injury Likely prerenal from diarrhea Admission creatinine 1.7; baseline creatinine 0.85   Diarrhea on admission Rectal bleeding Acute infectious/inflammatory colitis of unclear etiology Cause unknown; suspect colitis of unclear etiology.  CT abdomen pelvis on admission showed nonspecific colonic wall thickening could reflect portal hypertensive colopathy, infectious/inflammatory colitis or incomplete distention   Diabetes  Hypertension   AAA Followed with Dr.    Anxiety and depression   Obesity BMI: 36.32.   History of tobacco abuse